8.98
5.15%
+0.44
After Hours:
8.97
-0.010
-0.11%
Solid Biosciences Inc stock is currently priced at $8.98, with a 24-hour trading volume of 189.87K.
It has seen a +5.15% increased in the last 24 hours and a -33.82% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $8.37 pivot point. If it approaches the $9.04 resistance level, significant changes may occur.
Previous Close:
$8.54
Open:
$8.52
24h Volume:
189.87K
Market Cap:
$339.06M
Revenue:
$14.79M
Net Income/Loss:
$-96.02M
P/E Ratio:
-1.4539
EPS:
-6.1766
Net Cash Flow:
$-95.70M
1W Performance:
+3.22%
1M Performance:
-33.82%
6M Performance:
+349.00%
1Y Performance:
+91.06%
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
141 Portland Street, Fifth Floor, Cambridge, MA
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-12-21 | Initiated | Piper Sandler | Neutral |
May-27-21 | Initiated | Jefferies | Buy |
Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Mar-09-21 | Initiated | Barclays | Overweight |
Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
Oct-11-19 | Initiated | Evercore ISI | Outperform |
Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
May-14-19 | Downgrade | Goldman | Neutral → Sell |
Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Nov-06-18 | Initiated | Citigroup | Sell |
Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
Zacks Investment Research
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
GlobeNewswire Inc.
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
Benzinga
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
GlobeNewswire Inc.
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
Zacks Investment Research
Solid Biosciences Inc Stock (SLDB) Financials Data
Solid Biosciences Inc (SLDB) Revenue 2024
SLDB reported a revenue (TTM) of $14.79 million for the quarter ending June 30, 2022.
Solid Biosciences Inc (SLDB) Net Income 2024
SLDB net income (TTM) was -$96.02 million for the quarter ending December 31, 2023, a -11.67% decrease year-over-year.
Solid Biosciences Inc (SLDB) Cash Flow 2024
SLDB recorded a free cash flow (TTM) of -$95.69 million for the quarter ending December 31, 2023, a +5.24% increase year-over-year.
Solid Biosciences Inc (SLDB) Earnings per Share 2024
SLDB earnings per share (TTM) was -$4.84 for the quarter ending December 31, 2023, a +52.03% growth year-over-year.
About Solid Biosciences Inc
Solid Biosciences Inc. engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation. In addition, it is developing soft wearable assistive devices that have functional and therapeutic benefits to DMD patients. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):